VERDE SCIENCE STRENGTHENS SCIENTIFIC TEAM

Richmond, BC - October 02, 2014 - InvestorsHub NewsWire - Verde Science, Inc. (VRCI-OTCQB) a Medical Marijuana Research and Development Company, is pleased to announce the expansion of its Research and Development capabilities with the addition of its newest alliance partners, Dr. Ratnesh Jain and Dr. Prajatka Dandekar Jain, both of whom earned their Ph.D.’s in Pharmacology from the Institute of Chemical Technology, a Mumbai, India based University with a research focus along the entire spectrum of Chemical Engineering. Dr. Ratnesh Jain has investigated the development and design of novel drug delivery mechanisms which we believe will have significant applications in the nascent field of Medical Marijuana treatment. This could also be applied to clinical trials aimed at determining proper dosing and drug formulations for various specific medical issues.
Dr. Prajakta Dandekar Jain is an Assistant Professor of Pharmaceutical Technology at the Institute of Chemical Technology. In addition to research into novel drug delivery systems, she has also focused much of her research on nanoparticles, which will have particular relevance in the study of medical uses of THC and cannabinoids, and nanoparticles of hemp. Harp Sangha, Verde’s Chairman and CEO commented, “The addition of Drs. Jain to our current in-house R&D staff in Canada is going to be an immediate boost to our research program. It enables us to begin on research and clinical trials in India, which at the moment are on hold pending licensing in Canada. This gives Verde a huge advantage.”
Verde’s Research and Development Program will focus on developing custom medicinal formulations from cannabinoids and THC compounds for the treatment of specific issues such as migraines, glaucoma, loss of appetite from cancer therapies, and numerous other medical issues. Verde also plans to alpha test innovate growing technologies in India as part of the company’s initiatives. (A more extensive background statement for the Drs. Jain is available on the Verde Science website: www.VerdeScienceInc.com.)
About Verde Science, Inc. (VRCI)

Verde Science, Inc. (www.VerdeScienceInc.com) is a public company trading under the symbol OTCQB: VRCI. The Company is focused on Medical Marijuana Research and Development, and providing advisory services, quality assurance, and aeroponic growing systems in the burgeoning Medical Marijuana industry to established, licensed growers throughout Canada. The company has no operations anywhere in the United States, it only operates where the laws are clearly defined for this industry.

Safe Harbor Statements?Certain information contained in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates", "intends" or "believes", or that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur", or "be achieved". Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information please contact:

Harp Sangha, Chairman/CEO
1-858-210-0236
harpsangha@shaw.ca

Louis Silver, Director of Investor Relations
1-610-710-1303
lsilver@verdescienceinc.com